Identification of Waves by RF Magnetic Probes during Lower Hybrid Wave Injection Experiments on the TST-2 Spherical Tokamak

RF magnetic probes can be used to measure not only the wavevector, but also the polarization of waves in plasmas. A 5-channel RF magnetic probe (5ch-RFMP) was installed in the TST-2 spherical tokamak and the waves were studied in detail during lower hybrid wave injection experiments. From the polarization measurements, the poloidal RF magnetic field is found to be dominant. In addition to polarization, components of k perpendicular to the major radial direction were obtained from phase differences among the five channels. The radial wavenumber was obtained by scanning the radial position of the 5ch-RFMP on a shot by shot basis. The measured wavevector and polarization in the plasma edge region were consistent with those calculated from the wave equation for the slow wave branch. While the waves with small and large k∥ were excited by the antenna, only the small k∥ component was measured by the 5ch-RFMP; this suggests that the waves with larger k∥ were absorbed by the plasma

Rivaroxaban with or without aspirin in stable cardiovascular disease

BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS: In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. RESULTS: The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=−4.126), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (288 patients [3.1%] vs. 170 patients [1.9%]; hazard ratio, 1.70; 95% CI, 1.40 to 2.05; P<0.001). There was no significant difference in intracranial or fatal bleeding between these two groups. There were 313 deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 378 (4.1%) in the aspirin-alone group (hazard ratio, 0.82; 95% CI, 0.71 to 0.96; P=0.01; threshold P value for significance, 0.0025). The primary outcome did not occur in significantly fewer patients in the rivaroxaban-alone group than in the aspirin-alone group, but major bleeding events occurred in more patients in the rivaroxaban-alone group. CONCLUSIONS: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events